Research programme: inflammatory disease therapeutics - Janssen Biotech/X-Chem

Drug Profile

Research programme: inflammatory disease therapeutics - Janssen Biotech/X-Chem

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator X-Chem
  • Developer Janssen Biotech; X-Chem
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 15 Feb 2017 X-Chem expands collaboration with Janssen Biotech for the development of small molecules for the treatment of Inflammatory diseases
  • 30 Mar 2016 X-Chem enters into a licensing agreement with Janssen Biotech for protein inhibitor programme of Inflammatory disease
  • 09 Jan 2015 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top